Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-06-26 Board/Management Inform…
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Board/Management Information Classification · 100% confidence The document is a detailed notice of a postal ballot from Supriya Lifescience Limited dated June 26, 2024. It includes information about the voting process, dates, and special resolutions concerning changes in designation and appointment of key managerial personnel. The content focuses on corporate governance matters, specifically appointments and changes in senior management roles. There are no financial statements, earnings data, or audit information. The document is not a report but a formal announcement and solicitation of shareholder votes on management appointments. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-06-26 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a clarification about the company's financial results. It confirms the business segment of Supriya Lifescience Limited but does not contain any financial data, detailed results, or analysis. The document is short (1493 characters) and serves as a clarification or regulatory communication rather than a financial report or announcement of results. It does not fit into categories like Earnings Release, Interim Report, or Annual Report. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2024-06-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about a scheduled analyst/institutional investor meeting. It mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges. The document is short (2338 characters) and primarily serves as a notification of the meeting schedule and the availability of the presentation, rather than containing the presentation itself or detailed financial data. According to the rules, such notifications about investor meetings and presentations fall under Investor Presentation (IP) filings, as the document focuses on informing about the presentation and meeting details. Therefore, the classification is Investor Presentation (IP).
2024-06-17 English
Retirement
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015. It informs about the retirement of the Chief Executive Officer and Key Managerial Personnel, effective June 14, 2024. This is an announcement regarding a change in senior management personnel. The document is short (2170 characters) and does not contain financial data or detailed management discussion, so it is not an Annual Report, Interim Report, or Management Report. It is not a voting result, dividend notice, or any other category. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-06-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about scheduled meetings with analysts and institutional investors. It references the SEBI Listing Regulations and mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges. The document itself does not contain the presentation or detailed financial data but serves as an announcement of the upcoming investor meetings and the availability of the presentation elsewhere. The document length is only 2336 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE, this document should be classified as an Investor Presentation announcement. However, since it is not the presentation itself but an announcement about the schedule and availability of the presentation, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not contain the actual presentation content.
2024-06-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings call held on May 29, 2024, discussing the financial and operational performance of Supriya Lifescience Limited for the quarter and year ended March 31, 2024. It includes detailed financial figures such as revenue, EBITDA, profit before tax, and PAT for both the quarter and full fiscal year, as well as management commentary and Q&A with analysts. The presence of a full transcript of the conference call, including management remarks and Q&A, clearly identifies this as a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive financial data and discussion, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA). Therefore, the correct classification is Call Transcript (CT).
2024-06-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.